Abstrakt
Introduction. Metastatic disease represents the incurable stage for prostate cancer patients.
New treatment modalities have been invented and tested. They will supplement or even replace contemporary treatment procedures.
Dendritic cell based vaccines will play an important role in the treatment of prostate cancer patients. The aim of the study.
Summarize existing clinical studies utilizing dendritic cell vaccines in prostate cancer patients. Material and methods.
Analysis of published studies in medical literature and internet databases. Conclusion.
Dendritic cell vaccine based immunotherapy is a promising treatment alternative to prostate cancer patients, which needs further clinical evaluation. The future lies in the combination of dendritic cell vaccines and methods that lead to depletion of regulatory T-lymphocytes or change in tumor microenvironment.